Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The company will present new Phase 1 clinical data for its lead program, SENTI-202, at the American Association for Cancer Research (AACR) Annual Meeting on April 28, 2025 [1][2] Company Overview - Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies that enhance precision and control in targeting cancer cells while sparing healthy cells [3] - The company's pipeline includes cell therapies engineered with Gene Circuits aimed at challenging liquid and solid tumor indications, with SENTI-202 being a first-in-class off-the-shelf CAR NK cell therapy currently in Phase I clinical trials [3] Leadership and Communication - The upcoming conference call will be hosted by Timothy Lu, MD, PhD, CEO and Co-Founder, and Kanya Rajangam, MD, PhD, President and Chief Medical Officer [2] - Investors can access the conference call through a domestic and international dial-in number or via a webcast on the company's website, which will be archived for 90 days [2]